ABVC BIOPHARMA, INC. (ABVC): Nasdaq/NYSE listing notice — ABVC BioPharma receives Nasdaq deficiency letter for low stockholders' equity

ABVC BIOPHARMA, INC.

Stockholders' equity of $1.73M as of March 31, 2023, below Nasdaq's $2.5M minimum.
Company has until July 10, 2023 to submit compliance plan; possible extension to Dec 11, 2023.
No immediate effect on trading; common stock continues on Nasdaq under symbol ABVC.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

ABVC BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000, and the Company’s stockholders’ equity was $1,734,507 as of March 31, 2023. In accordance with Nasdaq rules, the Company has 45 calendar days, or until July 10, 2023, to submit a plan to regain compliance. If the plan is accepted,

View on SEC.gov

Browse all listing & compliance notices →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-043545

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.